Figure 5.

Cetuximab synergizes GC7 to promote its prolifereation inhibition in the epithelial HCC cell lines. A-C. Three epithelial HCC cell lines HepG2, Huh7 and Hep3B were treated with various doses of GC7, with or without additional cetuximab. D-F. EdU incorporation assay was performed to assess the proliferating abilities in GC7 (10 μM) - treated cells with or without cetuximab (IC₅₀ concentration in Table 2). G-I. Specific siRNA against STAT3 were employed to knock down the expression of STAT3 in the three cells HepG2, Huh7 and Hep3B. Cells were then treated with various doses of GC7 and were assessed for their viability under each condition. J. The knockdown efficacy of specific siRNA against STAT3 in HepG2, Huh7 and Hep3B cells (***, P<0.001).